Trinity Shares Forecast Modeling Expertise in New Article for In Vivo

Experts from Trinity Partners have published a bylined article in In Vivo. The article, titled, “You May Be Making These Drug Forecasting Mistakes,” breaks down the most common missteps in forecasting and highlights how to design and use the best models for the most accurate outcomes. In the article, Alex Chiang, Principal, and Adrian Watson, Senior Manager, Modeling and Analytics, discuss the top 10 most common drug forecasting errors, which fall into three broad categories: model design issues, model maintenance issues, and model abuse issues.  The authors also provide strategies to avoid these errors and achieve a successful forecasting process.

To view the full text of Alex and Adrian’s In Vivo article, please visit:

Trinity Partners to Acquire TGaS® Advisors

Click here to visit

Next milestone in Trinity’s build, buy and partner growth strategy further accelerates the firm’s mission and vision to lead transformation in the life sciences industry

Waltham, MA—Global life sciences consulting firm Trinity Partners today announced it has acquired TGaS® Advisors, the leading benchmarking and advisory services firm for commercial organizations in the life sciences industry. The acquisition marks another proof point in Trinity Partners’ overarching growth strategy and builds upon previous successes and momentum including a strengthened leadership team, U.S. and global expansion, and enhanced product offerings.

TGaS Advisors will operate as a wholly-owned division of Trinity Partners and brings to bear more than 15 years of industry experience including work with a majority of the top 50 pharmaceutical companies and a growing number of biotech companies. Under terms of the agreement, Trinity will add TGaS’s unique benchmarking products to its real-world evidence and primary market research capabilities to power its strategic advisory offerings in corporate and product strategy, launch readiness, pricing and market access, and health economics. The joint go-to-market offerings will enhance clients’ ability to deliver life changing innovations to patients around the globe.

“Our clients operate in a highly competitive marketplace. Their success hinges on ensuring they have the best strategic partner with industry expertise, insights, and analytics on their side,” said David Fitzhenry, CEO & Managing Partner, Trinity Partners.  “There is immediate benefit to our clients as we bring TGaS Advisors into the Trinity family and realize our combined potential. We look forward to expanding on their proven track record, built-in network and benchmarking capabilities and including them into our commercialization offerings.”

“Joining forces with Trinity Partners will undeniably make us a better and stronger collective entity not only for our clients and prospects, but also for our employees,” said Gary McWalters, President, TGaS Advisors. “I look forward to this next chapter as it is the perfect long-term scenario to accelerate investment in building our additional benchmarking offerings, delivering our vendor insights to the market and combining those core competencies with a strong Trinity portfolio that will improve the value proposition for our clients.”

“Moving forward, we will continue to target companies across new geographies to expand our influence, accelerate expansion, identify strategic adjacencies that expand collective influence and acquire outside talent and technology to offer new services to clients,” added Fitzhenry.

About TGaS Advisors

TGaS Advisors is the leading benchmarking and advisory services firm for commercial organizations in the life sciences industry. With a roster of more than 100 companies, including large, mid-tier, emerging and precommercial life sciences companies, TGaS provides robust comparative intelligence and collaborative network membership services. The team includes more than 50 experienced professionals, most with senior-level experience in the life sciences and related industries.

About Trinity Partners

Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. Trinity is partnered with Parthenon Capital Partners, a leading, growth-oriented private equity firm. To learn more about Trinity Partners, click here.


For Trinity Partners

Danielle Kirsch, 617-502-4372

Trinity Partners Welcomes Christian Frois, PhD to Leadership Team, Among 7 Leadership Team Promotions

Boston, August 20, 2018 – Leading global life sciences consulting firm Trinity Partners today announced that it has welcomed new Principal, Christian Frois, PhD, to the firm as well as seven other individuals to its leadership team. Trinity also welcomes new full-time hires, totaling 40 new employees company-wide this year to date.

Frois specializes in the development and evaluation of innovative commercial and evidence strategies for biopharmaceutical and medical device companies, and is a recognized expert on pricing, contracting and market access strategy. Prior to his appointment to principal at Trinity Partners, Frois was an assistant principal in the pharmaceuticals practice of CRA International. Over the course of his career, Frois has led numerous consulting engagements, developing U.S. and global launch, marketing, pricing, market access, and evidence generation strategies for medications across therapeutic areas, in both retail and institutional settings. Previously, Frois served as an assistant director at Ernst & Young in London, and a senior consultant with Mars & Co.  Frois has a Ph.D. in economics from Massachusetts Institute of Technology and an Ingénieur degree from Ecole Polytechnique, France.

Trinity also expanded its leadership team with the promotions of:

  • Eric Sholk from principal to partner. Sholk’s expertise ranges across areas that are critical to bringing products to market, as well as those that create additional value for clients through LCM and L&A opportunities.
  • Nandini Hadker from principal to partner. Hadker’s specializes in HEOR, RWE, primary and secondary research, and scientific publications.
  • Chad Faulkner from engagement manager to principal. Faulkner is an expert in licensing & acquisition, corporate strategy, pipeline and portfolio optimization, launch planning, market analytics, forecasting, and primary market research.
  • Kevin Chithran from engagement manager to principal. Chithran’s areas of specialization include market analytics, forecasting, new product planning, pipeline & portfolio optimization, and licensing & acquisition assessments.
  • Michelle Adams from director to senior director. Adams specializes in corporate communications, organizational planning, facilitated training, public speaking, instructional design, and performance management.

These 2018 additions to the leadership team follow the December 2017 promotions of Susheel Sukhtankar from engagement manager to principal, and John Gillis from associate director to principal. In addition to these promotions, Trinity Partners also welcomed 40 new full-time hires to the firm in 2018 thus far.

Based just outside of Boston, Trinity has more than 100 employees with offices in San Francisco and New York City, and has been named to Consulting Magazine’s list of ‘Fastest Growing Firms’ as well as a Boston Business Journal ‘Best Places to Work.’

About Trinity Partners

Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. To learn more about Trinity Partners, click here.

Trinity team attends Battle Summit to hear how Cycle for Survival funding is helping rare cancer patients

Trinity’s Breanna Liponis and Alyssa Blaize recently attended Battle Summit to hear firsthand from Memorial Sloan Kettering doctors and researchers how Cycle for Survival funding is helping rare cancer patients everywhere. The team heard about important studies, initiatives and clinical trials funded through Cycle for Survival donors and participants for salivary gland cancer, pancreatic neuroendocrine tumors and advanced melanoma, among other areas. In addition, the team heard the latest updates on Loxo Oncology’s TRK fusion inhibitor, larotrectinib, developed with Cycle for Survival funding, and its path to FDA approval. At Trinity Partners, we are proud to support Cycle for Survival to help advance rare cancer research. Learn more about Cycle for Survival: and read more about larotrectinib in our latest whitepaper:

Trinity Partners Named a Forbes Best Management Consulting Firm for Third Consecutive Year

Leading global life sciences consulting firm Trinity Partners today announced that it has been named to the Forbes America’s Best Management Consulting Firms 2018 list. Trinity Partners has been named among the best management consulting firms every year since the inaugural ranking in 2016.

The list, developed by Forbes in partnership with Statista, considers more than 1,300 consulting firms and surveys more than 1,000 senior executives to determine the best management consulting firms  based on recent performance and first-hand experience. The list represents 16 different industries including healthcare and life sciences.

“In today’s competitive environment, we’re proud to be recognized for the service we provide to our clients year after year,” said Dave Fitzhenry, CEO at Trinity Partners. “It’s a great reflection of our focus on customer satisfaction and strategic partnership, and we commend Forbes for putting the resources into this comprehensive list each year.”

Trinity works with more than 100 clients annually, including 18 of the top 25 global biopharmaceutical companies and dozens of leading medical device and diagnostic companies. Trinity has over 150 professionals on staff that focus solely on the life sciences industry.

To learn more about Trinity Partners, click here.

Trinity Partners Releases New Report on Oncology Basket Trials

Leading global life sciences consulting firm Trinity Partners today released a new whitepaper analyzing the oncology clinical trial pipeline to determine the extent to which basket trials are being utilized and, in particular, how many are likely to be registrational studies resulting in tissue-agnostic indications.

Historically, basket trials have been used to explore multiple tumor types in one trial in order to prioritize the ones with the greatest response for further research. However, with Keytruda’s MSI-H and dMMR approval, basket trials have now become a viable registrational strategy to pursue a tissue-agnostic indication. Key findings from the whitepaper include:

  • Only 2 trials appear to clearly be pursuing a tissue-agnostic regulatory filing; there are no basket trials currently in Phase III.
  • Although many of the trials identified are not clearly linked to a planned regulatory filing for a tissue-agnostic indication, the authors expect that the results of these trials, if positive in the broad indication, could lead to future registrational trials in the next 1-3 years.
  • Across the 37 basket trials identified for analysis, 16+ types of biomarkers or genetic mutations are currently being studied. This broad scope verifies the growing trend of tumor-agnostic research across oncologic agents, regardless of biomarker studied.

“In the near term, pending the results of these trials, interest in tissue-agnostic basket trial development is likely to grow, especially as next-generation genomic sequencing continues to become more widespread in oncology,” said Jillian Godfrey Scaife, principal at Trinity Partners. “Whether the number of tissue-agnostic indication approvals will ever be substantial enough to drive a significant shift in treatment approaches remains an open question.”

“With this research, we sought to better understand whether and when there will be a tipping point in the oncology treatment paradigm,” added Vivian DeWoskin, engagement manager. “The growing pool of mid-phase/exploratory tissue-agnostic trials suggests we could be headed in that direction, leading to many long-term implications on the clinical application, commercialization and development of targeted oncolytics in the next several years.”

Trinity works with more than 100 clients annually, including 18 of the top 25 global biopharmaceutical companies and dozens of leading medical device and diagnostic companies. Trinity has over 150 professionals on staff that focus solely on the life sciences industry.

To view the full whitepaper, click here.

Trinity Employees Share Expertise at Leading Spring Events and Conferences

Boston, MA, May 15, 2018 – Trinity Partners, a leading global life sciences consulting firm, today announced it will attend several important industry events across the U.S. this month. Covering topics ranging from innovation and endocrinology research to managed care, Trinity leaders are looking forward to presenting on and learning the latest updates in rare disease and patient advocacy, health care expenditure and the patient journey to continue to help clients make informed decisions in today’s continuously evolving business landscape.

Life sciences industry events Trinity Partners will attend include:

  • Intellus Worldwide Summit, May 6-8: Steve Yonish, Kyle Martin and Devon Reimer attended the Intellus Worldwide Summit in Philadelphia. The summit focused on new ways of understanding the patient journey including how insight professionals think about and provide solutions to optimize the patient experience.
  • Innovation Leader’s Deep Dive: Transforming Healthcare, May 16-17: Matt Giambrone will participate in the Innovation Leader’s Deep Dive at the Pulse@MassChallenge healthcare accelerator in Boston to hear best practices to better enable healthcare companies to successfully foster, pilot test and roll out new concepts.
  • American Association of Clinical Endocrinologists (AACE) 27th Annual Scientific and Clinical Congress, May 16-20: Irana Kolev will attend the AACE Scientific and Clinical Congress to hear the latest information on the diagnosis and management of endocrine diseases. Irana will also be presenting a poster for a recent Trinity health economics outreach research (HEOR) study on chronic hypoparathyroidism on May 19 from 10-11 am ET.
  • International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual Meeting, May 19-23: Nandini Hadker, Gavin Miyasato, Zahra Alkhateeb, Amod Athavale and Kalin Hennegan will be attending the ISPOR Annual Meeting in Baltimore to engage in the latest discussions around the role of real-world evidence and digital health in healthcare decision making. Trinity will also be presenting research in 3 poster presentations during ISPOR: a Medicare claims analysis quantifying the degree and impact of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer’s disease sub-specialization among neurologists, along with a Burden of Illness study and systematic literature review assessing the challenges with characterizing and managing hypoactive sexual desire disorder in women.

“At Trinity, we are committed to continuous learning and innovation to ensure we’re at the forefront of topics that matter to our clients,” said Yogesh Soneji, Partner, Trinity Partners. “We look forward to presenting research and continuing to find solutions to the complex business challenges that confront pharmaceutical, biotech, and medical device companies around the globe.”

Trinity Partners to Present on Patient Journey at Eyeforpharma Philadelphia 2018

Boston, MA, April 10, 2018 – Trinity Partners, a leading global life sciences consulting firm, today announced it will participate in eyeforpharma’s 16th Annual Meeting, April 10-11, in Philadelphia, PA.

This year’s eyeforpharma meeting is designed to provide life sciences executives with greater insight into the patient journey. Presenters will highlight strategies to leverage advanced analytics and communication channels and unite organizations around the patient to deliver real value.

“Treatments are becoming more targeted and patients are more involved in the treatment-decision-making process. Whether a product is launched or in clinical development, it’s vital that drug manufacturers understand a patient’s treatment journey from all perspectives – from the patient to the provider to the payer – to make more informed commercial decisions,” Kevin Francis, Principal, Analytics & Insights, Trinity Partners. “We look forward to attending eyeforpharma, connecting with members of the life sciences community and showcasing how to mine the patient journey for insights to guide commercial strategy decision-making.”

At eyeforpharma, Kevin Francis and Jenn Parr, Engagement Manager, will present on understanding and continuously refining the patient treatment journey to help manufacturers along the commercial decision-making process. The session, titled “Commercial Strategy Decision-Making powered by the Patient Journey” will be held on April 10, 2018 from 5:25-5:55 pm.

During the session, Kevin and Jenn will highlight how organizations can develop a patient journey framework that enables a common language across commercial teams, informs data strategy, and provides insights across the product development cycle. Kevin and Jenn will also showcase specific examples for organizations that have leveraged the patient journey for clinical, launch and post-launch decision-making purposes.

Visit Trinity at booth #4 at eyeforpharma to learn more about how you can begin to use the patient journey as the backbone for commercial decision-making.

Trinity employees will also attend several other events and conferences this month focused on gene therapy, rare diseases, specialty pharmacy and more. Events include:

  • The 2018 Yale Healthcare Conference: April 13, New Haven, CT
    • Nandini Hadker will speak on a panel on drug pricing.
  • The Academy of Managed Care Pharmacy (AMCP) 2018 Annual Meeting: April 23, Boston, MA
  • World Orphan Drug Congress USA: April 25, Oxon Hill, MD
  • Asembia’s 2018 Specialty Pharmacy Summit: April 29, Las Vegas, VM
  • The Gene Therapy for Rare Disorders Summit: April 29, Boston, MA

Trinity Partners Principal Jillian Godfrey Scaife Discusses Trinity Biosimilar Whitepaper

In a recent article for Managed Healthcare Executive, editor Tracey Walker spoke with Trinity’s Jillian Godfrey Scaife about the findings of Trinity’s recent biosimilar whitepaper. In the article, Jillian highlights key takeaways from the findings. You can read the full story including further insights from Jillian here: